Literature DB >> 10146985

The formulary decision-making process in a US academic medical centre.

D B Nash1, M L Catalano, C J Wordell.   

Abstract

This article reviews and describes the formulary decision-making process in an academic medical centre. The pharmacy and therapeutics (P & T) committee is the organisational nucleus of the drug use control process in the institutional environment. Thomas Jefferson University Hospital (TJUH), a 720-bed academic medical centre in an urban locality in the US, is used as a model representative of how most of these committees function. Survey responses collected from 29 peer academic medical centres are presented to compare and contrast the structure and function of the P & T committee at TJUH with corresponding procedures in other university hospitals in the US. TJUH is typical of the institutions which comprise the University Hospital Consortium (UHC). The P & T committee of TJUH is composed of 29 members, meets once per month for 10 months of the year, and has a network of 13 subcommittees. TJUH has an intermediately controlled (mixed) formulary, and uses both restricted drugs and treatment guidelines. Of the 29 UHC member institutions responding to the survey, the average P & T membership is 18, the average meeting frequency is 11 times per year, and 83% of these committees have a network of subcommittees. None describe their formulary system as open, 86% have a closed formulary and 14% have a mixed formulary system. There is a restricted drug programme in 76% of the institutions, 79% utilise treatment guidelines, 76% practice therapeutic interchange and all employ generic substitution. Specific areas addressed in this review include the history of the formulary system, the structure and function of the P & T committee, types of formularies, cost containment and the formulary decision-making process, the impact of organisational culture on physician decision making, the role of the pharmacy department, the role of pharmaceutical sales representatives and their impact on prescribing habits, the impact of the Joint Commission on Accreditation of Healthcare Organisations (JCAHO) Agenda for Change on the formulary process, and future challenges.

Entities:  

Mesh:

Year:  1993        PMID: 10146985     DOI: 10.2165/00019053-199303010-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  42 in total

1.  Guidelines on the operation of the pharmacy and therapeutics committee and formulary.

Authors:  J A Linkewich; S J Prevoznik
Journal:  Hosp Pharm       Date:  1979-01

2.  Therapeutic interchange as a cost-containment measure {editorial}.

Authors:  L E Achusim
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

3.  P & T Committee response to evolving technologies: preparing for the launch of high-tech, high-cost products. Roundtable discussion.

Authors:  J L Seltzer; C J Wordell; D Nash; N E Johnson; J E Gottlieb
Journal:  Hosp Formul       Date:  1992-04

4.  As hospital drug budgets soar, pharmacy's role is being rewritten.

Authors:  K Lumsdon
Journal:  Hospitals       Date:  1992-05-20

5.  ASHP statement on the formulary system.

Authors: 
Journal:  Am J Hosp Pharm       Date:  1986-11

6.  Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based "detailing".

Authors:  J Avorn; S B Soumerai
Journal:  N Engl J Med       Date:  1983-06-16       Impact factor: 91.245

7.  Pharmacy management strategies for responding to hospital reimbursement changes.

Authors:  F R Curtiss
Journal:  Am J Hosp Pharm       Date:  1983-09

8.  Coping with DRGs: Evanston Hospital, Evanston, Illinois.

Authors:  H E Lee
Journal:  Am J Hosp Pharm       Date:  1983-09

9.  Multiattribute evaluation in formulary decision making as applied to calcium-channel blockers.

Authors:  G E Schumacher
Journal:  Am J Hosp Pharm       Date:  1991-02

Review 10.  Information and education as determinants of antibiotic use: report of Task Force 5.

Authors:  J Avorn; K Harvey; S B Soumerai; A Herxheimer; R Plumridge; G Bardelay
Journal:  Rev Infect Dis       Date:  1987 May-Jun
View more
  7 in total

Review 1.  Reassessing the relevance of pharmacoeconomic analyses in formulary decisions.

Authors:  J A Johnson; E Friesen
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

2.  Pharmacoeconomics and formulary decision making.

Authors:  L A Sanchez
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 3.  The expanding role of pharmacy and therapeutics committees. The 1990s and beyond.

Authors:  W E Wade; W J Spruill; A T Taylor; R L Longe; D W Hawkins
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

4.  Reinventing the pharmacy and therapeutics committee.

Authors:  David Shulkin
Journal:  P T       Date:  2012-11

5.  The formulary decision-making process in a health maintenance organisation setting.

Authors:  M D Shepherd; R D Salzman
Journal:  Pharmacoeconomics       Date:  1994-01       Impact factor: 4.981

6.  The role of pharmacoeconomics in disease management. A pharmaceutical benefit management company perspective.

Authors:  N Thomas
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

7.  The case for an essential medicines list for Canada.

Authors:  Gina Eom; Paul Grootendorst; Jacalyn Duffin
Journal:  CMAJ       Date:  2016-06-13       Impact factor: 8.262

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.